首页 | 本学科首页   官方微博 | 高级检索  
     

Effects of cytotoxic T lymphocytes on hepatoma cell line SMMC-7721 induced by different subsets of dendritic cells in vitro
引用本文:Jia-Xiang Wang,Guang-Hui Liu,Ying-Zhong Fan,Qiu-Liang Liu,Juan Zhou,Dong-Yun Zhang and Yuan-Ming Qi Department of Surgery,First Affiliated Hospital of Zhengzhou University,Department of Pathophysiology and Department of Biological Engineering,Zhengzhou University,Zhengzhou 450052,China. Effects of cytotoxic T lymphocytes on hepatoma cell line SMMC-7721 induced by different subsets of dendritic cells in vitro[J]. Hepatobiliary & Pancreatic Diseases International, 2006, 0(3)
作者姓名:Jia-Xiang Wang  Guang-Hui Liu  Ying-Zhong Fan  Qiu-Liang Liu  Juan Zhou  Dong-Yun Zhang and Yuan-Ming Qi Department of Surgery  First Affiliated Hospital of Zhengzhou University  Department of Pathophysiology and Department of Biological Engineering  Zhengzhou University  Zhengzhou 450052  China
作者单位:Jia-Xiang Wang,Guang-Hui Liu,Ying-Zhong Fan,Qiu-Liang Liu,Juan Zhou,Dong-Yun Zhang and Yuan-Ming Qi Department of Surgery,First Affiliated Hospital of Zhengzhou University,Department of Pathophysiology and Department of Biological Engineering,Zhengzhou University,Zhengzhou 450052,China
摘    要:
BACKGROUND: Dendritic cells (DCs) loaded with complex antigen are always used to induce cytotoxic T lymphocytes (CTLs) which have a specific anti-tumor activity. However, CTLs can assault autologous cells induced by DCs loaded with autologous antigen. This study aimed to explore how to weaken the autoimmune reaction induced by DC vaccine by combining mature DC (mDC) activating immunity and immature DC (imDC) leading to immune tolerance to make hepatocellular carcinoma (HCC) vaccine in vitro. METHODS: DC progenitors derived from human peripheral blood were assigned to two groups. One was cultured to mDC and pulsed with frozen-thawed antigen (FTA) of human HCC cell line SMMC-7721 cells (mDC group), and the other was cultured to imDC and pulsed with FTA of human liver cell line L-02 cells (imDC group). The morphology of DCs was monitored and cells phenotypes including HLA-DR, CD80, CD1α, CD83 were assayed by flowcytometry (FCM). The concentrations of interleukin-12 (IL-12) in the supernatant were assayed by ELISA. Methyl thiazolyl tetrazolium (MTT) was used to evaluate T cell proliferation induced by mDC and imDC and the killing rate of CTL induced by mDC and imDC respectively/together on SMMC-7721 and L-02 cells. RESULTS: Compared with the imDC group, the mDC group was characterized by the following: increased secretion of IL-12 (P<0.05); higher expression of HLA-DR, CDla, CD80, CD83; and stronger activity in stimulating proliferation of isogenic T cells (P<0.05). CTL induced by the mDC group had a significant killing response to SMMC-7721 as well as a higher killing rate for L-02 (P>0.05). CTL induced by mDC and imDC together had a higher killing response to SMMC-7721, but a lower killing rate for L-02(P<0.01). CONCLUSIONS: CTL induced by mDC and imDC together has a higher antigen-specific killing response in vitro than that induced by mDC alone. This may be of greater clinical value.


Effects of cytotoxic T lymphocytes on hepatoma cell line SMMC-7721 induced by different subsets of dendritic cells in vitro
Jia-Xiang Wang,Guang-Hui Liu,Ying-Zhong Fan,Qiu-Liang Liu,Juan Zhou,Dong-Yun Zhang and Yuan-Ming Qi. Effects of cytotoxic T lymphocytes on hepatoma cell line SMMC-7721 induced by different subsets of dendritic cells in vitro[J]. 国际肝胆胰疾病杂志, 2006, 0(3)
Authors:Jia-Xiang Wang  Guang-Hui Liu  Ying-Zhong Fan  Qiu-Liang Liu  Juan Zhou  Dong-Yun Zhang  Yuan-Ming Qi
Affiliation:Jia-Xiang Wang,Guang-Hui Liu,Ying-Zhong Fan,Qiu-Liang Liu,Juan Zhou,Dong-Yun Zhang and Yuan-Ming Qi Department of Surgery,First Affiliated Hospital of Zhengzhou University,Department of Pathophysiology and Department of Biological Engineering,Zhengzhou University,Zhengzhou 450052,China
Abstract:
Keywords:dendritic cells  cancer vaccine  carcinoma   hepatocelluar  SMMC-7721 cell
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号